Meta AnalysisID 4511
川芎嗪治疗糖尿病肾脏疾病
CRD42012003285
Appraise the available evidence on the potential benefits and harms of Ligustrazine use in diabetic nephropathy.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 4511
- Evidence Id
- 13069
- Core Evidence Id
- 13069
- Source Meta Analysis Id
- 4481
- Herb2 Meta Analysis Id
- HBMA004481
- Crd Id
- CRD42012003285
- Title
- Ligustrazine for diabetic kidney disease
- Review Question
- Appraise the available evidence on the potential benefits and harms of Ligustrazine use in diabetic nephropathy.
- Study Type Included
- Parallel randomized controlled trials.
- Condition Being Studied
- Diabetic nephropathy is typically defined by albuminuria and abnormal renal function as represented by abnormality in blood urea nitrogen (BUN) and serum creatinine(SCr). Clinically, DN is characterized as high risk of cardiovascular morbidity and mortality.
- Participant
- Participants could be of any age, sex or ethnic origin, and DN had to be diagnosed according to recognized criteria.
- Animal
- Human Disease Modelled
- Intervention
- Ligustrazine was used in the treatment group or control group. But combination therapy of Ligustrazine and other interventions compared with the same other interventions alone was also included.
- Comparator Control
- No-treatment, placebo, nonpharmaceutical therapy or Western medications.
- Main Outcome
- Course of disease outcome and adverse events.
- Outcome Measure
- Additional Outcome
- Urinary microalbumin, Urinary protein, Urinary Albumin Excretion Rate, Serum Creatinine and Blood Urea Nitrogen.
- Study Method
- Intervention
- Keyword
- Diabetic Nephropathies; Drugs, Chinese Herbal; Humans; Kidney; Ligusticum; Pyrazines
- Contact
- Xie Liangzhen [email protected]
- Organisational Affiliation
- Funding Source
- None.
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English, Chinese-Simplified
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- Registration Date
- 2012-11-21
- Anticipated Start Date
- 2012-11-21
- Anticipated Completion Date
- 2013-12-31
- Title Cn
- 川芎嗪治疗糖尿病肾脏疾病
- Title En
- Ligustrazine for diabetic kidney disease
- Bilingual Status
- complete